The findings showed that ALS mice receiving hBMEPC vs. hBM34+ cell treatment significantly increased the levels of TJ claudin-5, occludin, and ZO-1 proteins; enhanced the coverage of capillary pericytes; amended immunoexpression of basement membrane laminin; and increased expression of endothelial cytoskeletal F-actin. The gene discussed is OCLN; the disease is amyotrophic lateral sclerosis.